Zilico winners of Bionow Investment Deal of the Year Award 2018
Thursday 29th November 2018
We are delighted and honoured to have been awarded Investment Deal of the Year in the Bionow 2018 Awards. The award, sponsored by QIAGEN, recognises our commitment to the company's continued growth and success and was accepted on the night by CEO Sameer Kothari. The investment and strategic partnership deal was a triparty deal between Deepbridge Capital, Maxhealth Medicine Group (China) and Zilico Limited. The deal will allow us to start our scaling ambitions and drive wider adoption of ZedScan, our flagship product within the cervical cancer pathway. The strategic partnership will see ZedScan deployed in the fastest growing medical device market, China, for which Zilico will receive minimum royalties of $12m. The investment also helps us to fund our FDA study for the largest medical device market.
With around 1100 life science and healthcare companies and a combined turnover of £10.9bn, the North of England’s life science sector has the breadth of business, depth of expertise and investment in specialist infrastructure that rivals anything that any other UK region can offer and the Bionow Awards recognises this success and achievement.